Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 2

被引:0
|
作者
Ton, Minh That [1 ]
Ho, Tri Huynh Quang [2 ]
Nguyen, Viet Lan [3 ]
Pham, Hung Manh [3 ,4 ]
Van Hoang, Sy [3 ,4 ]
Vo, Nhan Thanh [5 ,6 ]
Nguyen, Thai Quoc [3 ]
Pham, Linh Tran [3 ]
Mai, Ton Duy [4 ,7 ,8 ]
Nguyen, Thang Huy [9 ,10 ]
机构
[1] Tam Duc Heart Hosp, Ho Chi Minh City, Vietnam
[2] Heart Inst, Surg Intens Care Unit, Ho Chi Minh City, Vietnam
[3] Bach Mai Hosp, Vietnam Heart Inst, Hanoi, Vietnam
[4] Hanoi Med Univ, Hanoi, Vietnam
[5] Cho Ray Hosp, Cardiovasc Dept, Ho Chi Minh City, Vietnam
[6] Vinmec Hosp, Cardiovasc Ctr, Ho Chi Minh City, Vietnam
[7] Bach Mai Hosp, Stroke Ctr, Hanoi, Vietnam
[8] VNU Univ Med & Pharm, Hanoi, Vietnam
[9] Peoples 115 Hosp, Cerebro Vasc Dis Dept, 527 Hanh St,Dist 10,Ward 12, Ho Chi Minh City 700000, Vietnam
[10] Pham Ngoc Thach Univ Med, Ho Chi Minh City, Vietnam
关键词
Atrial fibrillation; renal impairment; diabetes; coronary artery disease; elderly; bioprosthetic valve; DIABETES-MELLITUS; ELDERLY-PATIENTS; EMBOLISM TRIAL; RENAL-FUNCTION; ANTITHROMBOTIC THERAPY; RISK STRATIFICATION; WARFARIN; OUTCOMES; RIVAROXABAN; DABIGATRAN;
D O I
10.15420/ecr.2023.25
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Part 1 of this review provided an overview of AF in Vietnam, with a particular focus on primary and secondary stroke prevention. Part 2 explores the management of AF in special, high-risk and clinically common patient populations, including those with renal impairment, diabetes, the elderly, and those with coronary artery disease. Furthermore, Part 2 addresses the challenges posed by patients with AF who have a bioprosthetic valve, a group situated in a grey area of consideration. Managing AF in these patient groups presents unique clinical challenges that require careful consideration. Physicians are tasked with addressing specific clinical questions to identify the optimal anticoagulation strategy for each individual. To inform these decisions, subgroup analyses from pivotal studies are presented alongside real-world data derived from clinical practice. By synthesising available information and considering the nuanced clinical context, the aim is to provide informed perspectives that align with current medical knowledge and contribute to the enhancement of patient care in these challenging scenarios.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation
    Diener, Hans-Christoph
    Hankey, Graeme J.
    Easton, J. Donald
    Lip, Gregory Y. H.
    Hart, Robert G.
    Caso, Valeria
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0I) : I13 - I21
  • [42] Adherence to oral anticoagulant therapy in patients with atrial fibrillation Focus on non-vitamin K antagonist oral anticoagulants
    Raparelli, Valeria
    Proietti, Marco
    Cangemi, Roberto
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    Basili, Stefania
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (02) : 209 - 218
  • [43] Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation A Review
    Eikelboom, John W.
    Quinlan, Daniel J.
    Hirsh, Jack
    Connolly, Stuart J.
    Weitz, Jeffrey I.
    JAMA CARDIOLOGY, 2017, 2 (05) : 566 - 574
  • [44] Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal
    Costa, Joao
    Fiorentino, Francesca
    Caldeira, Daniel
    Ines, Monica
    Pereira, Catarina Lopes
    Pinheiro, Luis
    Vaz-Carneiro, Antonio
    Borges, Margarida
    Gouveia, Miguel
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2015, 34 (12) : 723 - 737
  • [45] Risk of recurrent stroke for Asian stroke patients treated with non-vitamin K antagonist oral anticoagulant and warfarin
    Lin, Sheng-Feng
    Lu, Yi-Hsuan
    Bai, Chyi-Huey
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2020, 11
  • [46] Non-vitamin K oral antagonist failure and tailored treatment in patients with atrial fibrillation and stroke
    Kim, Hyung Jun
    Choi, Soyoun
    Kim, Hee-Jin
    Bang, Oh Young
    PRECISION AND FUTURE MEDICINE, 2020, 4 (01): : 37 - 42
  • [47] Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients
    Zhu, Wengen
    Ye, Zi
    Chen, Shilan
    Wu, Dexi
    He, Jiangui
    Dong, Yugang
    Lip, Gregory Y. H.
    Liu, Chen
    STROKE, 2021, 52 (04) : 1225 - 1233
  • [48] Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants The Stockholm Experience
    Forslund, Tomas
    Komen, Joris J.
    Andersen, Morten
    Wettermark, Bjorn
    von Euler, Mia
    Mantel-Teeuwisse, Aukje K.
    Braunschweig, Frieder
    Hjemdahl, Paul
    STROKE, 2018, 49 (09) : 2122 - 2128
  • [49] Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
    Lee, Ki Hong
    Park, Hyung Wook
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (05) : 583 - 594
  • [50] Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease
    Renda, Giulia
    Ricci, Fabrizio
    Giugliano, Robert P.
    De Caterina, Raffaele
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1363 - 1371